These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11567739)

  • 1. Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response.
    Morris CB; Thanawastien A; Sullivan DE; Clements JD
    Vaccine; 2001 Oct; 20(1-2):12-5. PubMed ID: 11567739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin.
    Caputo A; Brocca-Cofano E; Castaldello A; Voltan R; Gavioli R; Srivastava IK; Barnett SW; Cafaro A; Ensoli B
    Vaccine; 2008 Feb; 26(9):1214-27. PubMed ID: 18243435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
    McKinney DM; Skvoretz R; Livingston BD; Wilson CC; Anders M; Chesnut RW; Sette A; Essex M; Novitsky V; Newman MJ
    J Immunol; 2004 Aug; 173(3):1941-50. PubMed ID: 15265928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice.
    Cellini S; Fortini C; Gallerani E; Destro F; Cofano EB; Caputo A; Gavioli R
    Virol J; 2008 Jul; 5():81. PubMed ID: 18625037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
    Morris CB; Cheng E; Thanawastien A; Cárdenas-Freytag L; Clements JD
    Vaccine; 2000 Mar; 18(18):1944-51. PubMed ID: 10699345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helper T-cell recognition of HIV-1 Tat synthetic peptides.
    Blazevic V; Ranki A; Mattinen S; Valle SL; Koskimies S; Jung G; Krohn KJ
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):881-90. PubMed ID: 7686223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.
    Simmons CP; Hussell T; Sparer T; Walzl G; Openshaw P; Dougan G
    J Immunol; 2001 Jan; 166(2):1106-13. PubMed ID: 11145691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.
    Marinaro M; Riccomi A; Rappuoli R; Pizza M; Fiorelli V; Tripiciano A; Cafaro A; Ensoli B; De Magistris MT
    Vaccine; 2003 Sep; 21(25-26):3972-81. PubMed ID: 12922133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.
    Dominici S; Laguardia ME; Serafini G; Chiarantini L; Fortini C; Tripiciano A; Brocca-Cofano E; Scoglio A; Caputo A; Fiorelli V; Gavioli R; Cafaro A; Ensoli B; Magnani M
    Vaccine; 2003 May; 21(17-18):2073-81. PubMed ID: 12706697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.
    Neidleman JA; Vajdy M; Ugozzoli M; Ott G; O'Hagan D
    Immunology; 2000 Sep; 101(1):154-60. PubMed ID: 11012767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.
    Caputo A; Gavioli R; Altavilla G; Brocca-Cofano E; Boarini C; Betti M; Castaldello A; Lorenzini F; Micheletti F; Cafaro A; Sparnacci K; Laus M; Tondelli L; Ensoli B
    Vaccine; 2003 Mar; 21(11-12):1103-11. PubMed ID: 12559787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.